专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008150701A1 DETERMINING SEAL FEATURE INTEGRITY BY TESTING FOR DEFORMATION UPON AIR PRESSURE EXCITATION 审中-公开
标题翻译：通过测试空气压力激励的变形来确定密封特性的完整性
公开(公告)号：WO2008150701A1
公开(公告)日：2008-12-11
申请号：PCT/US2008/064257
申请日：2008-05-20
申请人： THE BOEING COMPANY , SAFAI, Morteza , GEORGESON, Gary, E. , LEE, James, H. , LEA, Scott, W.
发明人： SAFAI, Morteza , GEORGESON, Gary, E. , LEE, James, H. , LEA, Scott, W.
IPC分类号： G01M3/36
CPC分类号： G01M3/363 , G01M3/38
摘要： Optical metrology methods, apparatuses, and systems for detecting seal integrity. These comprise changing an air pressure inside a chamber to an excitation pressure level when the chamber is placed over a segment of a surface of a structure having one or more seal features and determining whether the integrity of any of the one or more seal features has been compromised by determining, using an optical system, whether any of the one or more seal features have been deformed by the changing of the air pressure.
摘要翻译：用于检测密封完整性的光学测量方法，设备和系统。这些包括当腔室被放置在具有一个或多个密封特征的结构的表面的段上时，将室内的空气压力改变到激发压力水平，并且确定一个或多个密封特征中的任何一个的完整性是否已被通过使用光学系统确定一个或多个密封特征中的任何一个是否已经由于空气压力的变化而变形而受损。

2. 发明申请

WO2004051764A2 CORROSION RESISTANT PEM FUEL CELL 审中-公开
标题翻译：耐腐蚀PEM燃料电池
公开(公告)号：WO2004051764A2
公开(公告)日：2004-06-17
申请号：PCT/US2003/038031
申请日：2003-12-01
申请人： GENERAL MOTORS CORPORATION , LEE, James, H. , BRADY, Brian, K. , FUSS, Robert, L.
发明人： LEE, James, H. , BRADY, Brian, K. , FUSS, Robert, L.
IPC分类号： H01M
CPC分类号： H01M8/0228 , H01M8/0206 , H01M8/0213 , H01M8/0221 , H01M8/0226 , H01M8/0247 , H01M2008/1095
摘要： The present invention relates to an electrochemical cell having a catalytic electrode and an electrically conductive contact element facing the electrode. The electrically conductive contact element conducts electrical current from the electrode and has a surface comprising a plurality of passivated regions, and a plurality of non-passivated regions dispersed among the passivated regions. The surface further is coated with an electrically conductive, corrosion resistant coating. Other preferred aspects of the present invention include methods of treating the electrically conductive contact element by passivation to resist corrosion while still maintaining electrical conductivity.
摘要翻译：本发明涉及具有催化电极和面向电极的导电接触元件的电化学电池。导电接触元件从电极传导电流，并且具有包括多个钝化区域的表面和分布在钝化区域中的多个非钝化区域。该表面进一步涂覆有导电的耐腐蚀涂层。本发明的其它优选方面包括通过钝化处理导电接触元件以抵抗腐蚀同时仍然保持导电性的方法。

3. 发明申请

WO2010080345A1 LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING ACTINIC KERATOSIS 审中-公开
标题翻译：较低剂量强度液体制剂和短期剂量治疗药物治疗方案
公开(公告)号：WO2010080345A1
公开(公告)日：2010-07-15
申请号：PCT/US2009/067759
申请日：2009-12-11
申请人： GRACEWAY PHARMACEUTICALS, LLC , NORDSIEK, Michael, T. , LEVY, Sharon, F. , LEE, James, H. , KULP, James, H. , BALAJI, Kodumudi, S. , MENG, Tze-Chiang , WU, Jason, J. , BAHM, Valyn, S. , BABILON, Robert
发明人： NORDSIEK, Michael, T. , LEVY, Sharon, F. , LEE, James, H. , KULP, James, H. , BALAJI, Kodumudi, S. , MENG, Tze-Chiang , WU, Jason, J. , BAHM, Valyn, S. , BABILON, Robert
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/4745 , A61K9/0014 , A61K9/06 , A61K9/7061 , A61K31/437 , A61K31/47 , A61K47/10 , A61K47/12 , A61K47/14
摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1 H -imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylρropyl)- 1 H -imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara ® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara ® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
摘要翻译：用于局部或透皮递送1-异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基羰基）-1H-咪唑并[4,5 -c]喹啉-4-胺，即咪喹莫特，用于治疗短时间疗法的光化性角化病，比目前为市售的5％咪喹莫特乳膏所规定的，如美国食品和药物管理局（FDA）批准 “），被公开和描述。更具体地说，低剂量强度咪喹莫特制剂以比目前美国食品和药物管理局（FDA）批准的给药方案递送有效剂量的咪喹莫特用于治疗光化性角化病，具有可接受的安全性和对患者使用而言更方便的给药方案还公开和描述了用于Aldara 5％咪喹莫特乳膏治疗光化性角化病的“FDA”）。

4. 发明申请

WO2009085395A1 METHODS AND SYSTEMS FOR DETERMINING NEAR-WELLBORE CHARACTERISTICS AND RESERVOIR PROPERTIES 审中-公开
标题翻译：用于确定近井特性和储层特性的方法和系统
公开(公告)号：WO2009085395A1
公开(公告)日：2009-07-09
申请号：PCT/US2008/082249
申请日：2008-11-03
申请人： EXXONMOBIL UPSTREAM RESEARCH COMPANY , POSTL, Dieter , BURDETTE, Jason, A. , LEE, James, H. , BENISH, Timothy, G. , DALE, Bruce, A.
发明人： POSTL, Dieter , BURDETTE, Jason, A. , LEE, James, H. , BENISH, Timothy, G. , DALE, Bruce, A.
IPC分类号： G06G7/48
CPC分类号： E21B49/00
摘要： Systems and methods are provided for determining a reservoir property distinct from a near-wellbore/completion characteristic. The methods include obtaining non-transient well data regarding a measurable characteristic of a well that is used to establish a functional relationship between a reservoir property, a near-wellbore/completion characteristic, and the measurable characteristic of the well. A model that relates the reservoir property and the near-wellbore/completion characteristic is used to generate a modeled near- wellbore/completion characteristic value from an input reservoir property value, or vice versa. The input value and the modeled value are then tested against the well data using the functional relationship. The model is used repeatedly with different input values until a validated reservoir property value and a validated near-wellbore/completion characteristic value are identified that at least substantially satisfy the functional relationship. The validated reservoir property value and the validated near-wellbore/completion characteristic are reported for use in business decisions regarding one or more wells.
摘要翻译：提供了用于确定与近井眼/完井特性不同的油藏性质的系统和方法。这些方法包括获得关于用于建立储层性质，近井眼/完井特征和井的可测量特征之间的功能关系的井的可测量特征的非瞬态井数据。将油藏性质和近井眼/完井特征相关联的模型用于从输入油藏属性值产生建模的近井眼/完井特征值，反之亦然。然后使用功能关系针对井数据对输入值和建模值进行测试。该模型反复使用不同的输入值，直到确定了至少基本上满足功能关系的验证的储层特性值和验证的近井眼/完井特征值。报告了经验证的油藏物性值和验证的近井眼/完井特征，用于关于一个或多个井的业务决策。

5. 发明申请

WO2008118765A1 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：当使用IMIQUIMOD治疗患有皮肤病的儿童时，加强安全的方法和包装
公开(公告)号：WO2008118765A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/057761
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS, LLC , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatological disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了当用于治疗受皮肤病症影响的儿童时用于增强咪喹莫特安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L。咪喹莫特的局部和/或透皮递送，包括霜剂，软膏，凝胶，洗剂，药膏和压敏粘合剂组合物，用于治疗儿童皮肤病，即传染性软疣，病毒感染如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，并诱导干扰素生物合成。

6. 发明申请

WO2008118762A1 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：当使用IMIQUIMOD治疗患有皮肤病的儿童时，加强安全的方法和包装
公开(公告)号：WO2008118762A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/057758
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS, LLC , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat chiidren affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatologica! disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了用于增强咪喹莫特用于治疗受皮肤疾病影响的儿童的安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L。局部和/或透皮给药咪喹莫特，包括霜剂，软膏，凝胶，洗剂，药膏和压敏胶粘剂组合物以治疗皮肤病！公开了儿童疾病，即传染性软体动物，病毒感染，例如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，以及诱导干扰素生物合成。

7. 发明申请

WO2003092107A1 COOLANT FLOW FIELD DESIGN FOR FUEL CELL STACKS 审中-公开
标题翻译：燃料电池堆的冷却液流场设计
公开(公告)号：WO2003092107A1
公开(公告)日：2003-11-06
申请号：PCT/US2003/010120
申请日：2003-04-01
申请人： GENERAL MOTORS CORPORATION , LEE, James, H.
发明人： LEE, James, H.
IPC分类号： H01M8/04
CPC分类号： H01M8/04074 , H01M8/0202 , H01M8/04029
摘要： A bipolar plate assembly is provided for use in a fuel cell stack to supply reactants to the anode and cathode sides of fuel cells within the stack. The bipolar plate assembly includes first and second sub-plates, each including a first face surface having a coolant flow field formed therein and a second face surface having a reactant flow field formed therein. The coolant fields of the first and second sub-plates include regions of varying flow volume, having respective flow resistance therebetween. The regions of varying flow volume enable variable cooling across the fuel cell stack, thereby enabling a constant temperature to be achieved across the fuel cell stack.
摘要翻译：提供了用于燃料电池堆中的双极板组件，以将反应物供应到堆叠内的燃料电池的阳极和阴极侧。双极板组件包括第一和第二子板，每个子板包括形成在其中的冷却剂流场的第一面表面和在其中形成有反应物流场的第二表面。第一和第二子板的冷却剂区域包括具有不同流量的区域，其间具有相应的流动阻力。不同流量的区域使得能够跨越燃料电池堆的可变冷却，由此能够实现跨燃料电池堆的恒定温度。

8. 发明申请

WO2008118881A1 METHOD AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：使用IMIQUIMOD治疗患有皮肤病的儿童治疗儿童时，加强安全的方法和包装
公开(公告)号：WO2008118881A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/058070
申请日：2008-03-24
申请人： GRACEWAY PHARMACEUTICALS, LLC , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatological disorders in children, namely, molluscum contagiosum, viral infections, such as Type 1 or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了当用于治疗受皮肤病症影响的儿童时用于增强咪喹莫特安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L本文和/或透皮给药咪喹莫特，包括霜剂，软膏，凝胶，洗剂，药膏和压敏粘合剂组合物，用于治疗儿童皮肤病，即传染性软疣，病毒感染例如1型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，以及诱导干扰素生物合成。

9. 发明申请

WO2008118763A1 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：当使用IMIQUIMOD治疗患有皮肤病的儿童时，加强安全的方法和包装
公开(公告)号：WO2008118763A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/057759
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS, LLC. , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatological disorders in children, namely, moiluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal ceil carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了当用于治疗受皮肤病症影响的儿童时用于增强咪喹莫特安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L。咪喹莫特的局部和/或透皮递送，包括霜剂，软膏，凝胶，洗剂，药膏和压敏粘合剂组合物，用于治疗儿童皮肤病，即传染性疾病，病毒感染如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，并诱导干扰素生物合成。

10. 发明申请

WO2003100885A1 COOLING SYSTEM FOR A FUEL CELL STACK 审中-公开
标题翻译：燃料电池堆的冷却系统
公开(公告)号：WO2003100885A1
公开(公告)日：2003-12-04
申请号：PCT/US2003/014767
申请日：2003-05-12
申请人： GENERAL MOTORS CORPORATION , LEE, James, H. , SKALA, Glenn, W.
发明人： LEE, James, H. , SKALA, Glenn, W.
IPC分类号： H01M2/02
CPC分类号： H01M8/04029 , F28D2021/0043 , F28D2021/0064 , F28F3/048 , F28F3/12 , F28F13/08 , H01M8/0263 , H01M8/0265 , H01M8/0267 , H01M8/242 , H01M2250/20 , Y02T90/32
摘要： A fuel cell cooling system (72) is provided with a coolant pump (74) for pumping fluid through coolant flow field passages (76) in a fuel cell stack (70). A pressure control mechanism is provided for maintaining a pressure level within the fuel cell stack (70) for causing a phase change of the coolant within the stack (70). Allowing the coolant to change phase to a gas inside the stack (70) reduces the amount of coolant needed to cool the fuel cell stack (70) and thereby reduces the energy needed to pump the coolant through the fuel cell stack (70).
摘要翻译：燃料电池冷却系统（72）设置有用于将流体泵送通过燃料电池堆（70）中的冷却剂流场通道（76）的冷却剂泵（74）。提供了一种压力控制机构，用于保持燃料电池堆（70）内的压力水平，用于使堆叠（70）内的冷却剂相变。允许冷却剂将相改变成堆（70）内的气体减少了冷却燃料电池堆（70）所需的冷却剂的量，从而降低了将冷却剂泵送通过燃料电池堆（70）所需的能量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式